Welcome

Full Pfizer Vaccine Approval Possible by Fall, NIH Head Says

July 19, 2021, 4:31 PM

Full approval of Pfizer Inc.'s Covid-19 vaccine could happen as early as the end of the summer, months ahead of the January 2022 target date, NIH Director Francis S. Collins said Monday.

Collins’ remarks follow the pharmaceutical giant’s announcement last week that it received priority review and that the Food and Drug Administration would decide whether to approve Pfizer’s vaccine for people 16 and older by early next year.

The January 2022 target date has to do with the schedule laid out in the FDA’s current agreement over user fees, which are funds the agency collects from drug and device ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.